- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05404880
INSPIRIS Китайское исследование PMCF (INSPIRIS China)
Послепродажное клиническое последующее исследование аортального клапана Edwards Lifesciences INSPIRIS RESILIA у населения Китая
The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100037
- Fuwai Hospital, CAMS & PUMC
-
Beijing, Beijing Municipality, Китай, 100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Fujian
-
Xiamen, Fujian, Китай, 361008
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510080
- The First Affiliated Hospital, Sun Yat-sen University
-
Shenzhen, Guangdong, Китай, 518038
- Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
-
-
Henan
-
Zhengzhou, Henan, Китай, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, Китай, 450008
- Henan Provincial Chest Hospital
-
Zhengzhou, Henan, Китай, 451460
- Fuwai Central China Cardiovascular Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210012
- Nanjing First Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, Китай, 710065
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610072
- Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
-
-
Yunnan
-
Kunming, Yunnan, Китай, 650102
- Fuwai Yunnan Cardiovascular Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.
Описание
Inclusion Criteria:
- Subject is 18 years or older
- Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
- Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
- Provide signed informed consent prior to the study participation
Exclusion Criteria:
- Valve implantation is contraindicated per the IFU
- Requires planned multiple valve replacement/ repair
- Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
- Estimated Life expectancy< 12 months
- Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
EDWARDS INSPIRIS RESILIA Aortic Valve
Subjects who were treated with the INSPIRIS RESILIA aortic heart valve. |
Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Subject's Occurrence Rate of Study Valve Related Death
Временное ограничение: 10 Years
|
The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death. |
10 Years
|
|
Subject's Occurrence Rate of Structural Valve Deterioration
Временное ограничение: 10 Years
|
The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation. |
10 Years
|
|
Subject's Occurrence Rate of Re-operation on the Study Valve
Временное ограничение: 10 Years
|
The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room. |
10 Years
|
|
Subject's Occurrence Rate of Major Bleeding
Временное ограничение: 10 Years
|
The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding. |
10 Years
|
|
Subject's Occurrence Rate of Thromboembolic Events
Временное ограничение: 10 Years
|
The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event. |
10 Years
|
|
Subject's Occurrence Rate of Stroke
Временное ограничение: 10 Years
|
The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans. |
10 Years
|
|
Subject's Occurrence Rate of Transient Ischemic Attack
Временное ограничение: 10 Years
|
The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration. |
10 Years
|
|
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
Временное ограничение: 10 Years
|
The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis). |
10 Years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Subject's Average Mean Gradient at 10 Years
Временное ограничение: 10 Years
|
Hemodynamic performance - Mean gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Peak Gradient at 10 Years
Временное ограничение: 10 Years
|
Hemodynamic performance - Peak gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area at 10 Years
Временное ограничение: 10 Years
|
Hemodynamic performance - Effective Orifice Area evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area Index at 10 Years
Временное ограничение: 10 Years
|
Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Central Regurgitation in Subjects at 10 Years
Временное ограничение: 10 Years
|
Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
Временное ограничение: 10 Years
|
Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography |
10 Years
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Hansong Sun, Professor, Chinese Academy of Medical Sciences, Fuwai Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- 2021-09
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Individual participant data will not be available to other researchers.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .